Related Experiment Videos

[Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?]

Ioana Dana Alexa1, Larisa Panaghiu, G Ungureanu

  • 1Facultatea de Medicină, Clinica a IV-a Medicală-Nefrologie, Universitatea de Medicină si Farmacie "Gr. T. Popa", Iaşi.

Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi
|April 14, 2006
PubMed

Insights

Hydroxymethylglutaryl coenzyme A reductase inhibitors combined with diet effectively manage dyslipidemia in elderly patients. This combination therapy significantly lowers cholesterol and triglycerides, reducing cardiovascular risks better than diet alone due to improved patient adherence.

Area of Science:

  • Geriatric Medicine
  • Cardiovascular Pharmacology
  • Metabolic Disorders

Background:

  • Elderly patients are at increased risk for sudden death, myocardial infarction, and stroke.
  • Dyslipidemia is a major independent risk factor for cardiovascular diseases.
  • Effective cholesterol management reduces cardiovascular event risk and improves other risk factors like hypertension and diabetes.

Purpose of the Study:

  • To evaluate the efficacy of hydroxymethylglutaryl coenzyme A reductase inhibitors (simvastatin) combined with diet in treating dyslipidemia in elderly patients.
  • To compare the effectiveness of diet alone versus diet plus statin therapy.
  • To assess the impact on cardiovascular risk factors in the elderly population.

Main Methods:

  • A retrospective study involving 84 patients aged 65 years and older with high cholesterol, triglycerides, and LDL-C/HDL-C ratio.
  • Patients were divided into two groups: diet only (Group I, n=40) and diet plus simvastatin 10 mg/day (Group II, n=44).
  • Lipid profiles were monitored at baseline, 3 weeks, and 6 weeks.

Main Results:

  • Diet alone resulted in modest reductions in cholesterol and triglycerides, with declining patient compliance.
  • The combination therapy group showed significant reductions in cholesterol and triglycerides after 3 weeks.
  • 72% of patients in Group II achieved a normal lipid profile after 6 weeks; no side effects were reported.

Conclusions:

  • Hydroxymethylglutaryl coenzyme A reductase inhibitors combined with a hypocholesterolemic diet efficiently control dyslipidemia in elderly patients.
  • Dietary interventions alone were less effective due to poor patient adherence.
  • Statin therapy offers significant benefits for elderly patients due to efficacy, minimal side effects, and protection against major cardiovascular events.
Abstract

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...